By Fineline Cube 
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted R&D Agreement with compatriot firm FBC (Shanghai) Pharmaceutical Technology Co., Ltd. The agreement relates to the MF59 emulsion adjuvant, which Buchang Pharma is developing as part of a Category II vaccine.
Agreement Details
Under the accord, Buchang Pharma, which is developing a vaccine with MF59 as the adjuvant, will entrust FBC Pharma to conduct partial research on MF59 during the Investigational New Drug (IND) and New Drug Application (NDA) stages. Buchang Pharma will pay RMB 1.2 million (USD 166,378) and RMB 300,000 (USD 41,597) during the respective stages.
Commercialization Stage
In the commercialization stage, Buchang Pharma will be responsible for the production, self-inspection, batch issuance application, and commercialization activities of the vaccine. Buchang Pharma will also pay a maximum sales commission of RMB 20 million (USD 2.8 million) to FBC Pharma.-Fineline Info & Tech